Search results
Results from the WOW.Com Content Network
[115] [116] [117] AstraZeneca responded to the criticism by agreeing to carry out a new multi-country trial using the lower dose, which had led to the 90% claim. [ 118 ] The full publication of the interim results from four ongoing Phase III trials on 8 December allowed regulators and scientists to begin evaluating the vaccine's efficacy. [ 119 ]
(Reuters) -AstraZeneca said its COVID-19 vaccine sales were $275 million in the first-quarter and it is on track to deliver 200 million doses a month from April, as better-than-expected results ...
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [13]
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
AstraZeneca is advancing early stage trials of several cell therapies in different types of cancer including liver and prostate cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak ...
The trial, known as CAPItello-290, was testing whether the drug combination improved overall survival in patients with inoperable or metastatic triple-negative breast cancer versus the older and ...
The U.S. government chose not to include Operation Warp Speed as part of the international Solidarity trial on vaccine development, organized by the WHO. [ 4 ] President Trump displays Executive Order 13962, which requires priority access to COVID-19 vaccines developed in the United States, signed December 8, 2020
The trial, known as ADJUVANT BR.31 Phase III, sought to evaluate Imfinzi in the adjuvant treatment of 1,415 patients with an early stage of non-small-cell lung cancer following complete tumour ...